Which drugs can produce a Bartter-type electrolyte picture?

Drugs Causing Bartter-Like Electrolyte Picture

Loop diuretics (furosemide, bumetanide) and aminoglycosides (particularly gentamicin) are the most common drugs causing Bartter-like syndrome, followed by polymyxins (colistin, polymyxin B), amphotericin B, and calcineurin inhibitors (tacrolimus, cyclosporine).

Primary Drug Classes

Diuretics

• Loop diuretics are the classic cause of pseudo-Bartter syndrome 1
• These directly inhibit the NKCC2 transporter in the thick ascending limb, mimicking the genetic defect in Bartter syndrome type 1
• Thiazide diuretics can also produce similar electrolyte patterns but affect the distal convoluted tubule instead 1

Aminoglycosides

• Gentamicin is the most frequently implicated antimicrobial (41.8% of reported cases) 2
• Median onset: 10 days after drug exposure (IQR 7-18 days) 2
• Resolution typically occurs within 14 days (IQR 7-31 days) after discontinuation 2
• Other aminoglycosides (tobramycin, amikacin) can cause similar effects

Polymyxins

• Colistin accounts for 32.5% of antibiotic-induced Bartter-like syndrome cases 2
• Polymyxin B causes tubular dysfunction despite being considered "less nephrotoxic" than colistin 3, 4
• Onset typically within 3-6 days of therapy 5, 3
• Can cause life-threatening complications including torsades de pointes from severe electrolyte depletion 5

Calcineurin Inhibitors

• Tacrolimus and cyclosporine cause tubular dysfunction in transplant recipients 6
• Presents with losing-salt tubulopathy requiring chronic electrolyte replacement
• Dose-dependent effect: reducing dose improves metabolic profile, but increasing dose worsens electrolyte disturbances 6

Other Antimicrobials

• Amphotericin B causes renal tubular dysfunction 2

Clinical Recognition Pattern

The characteristic electrolyte picture includes:

• Hypokalemia (100% of cases) 2
• Metabolic alkalosis (97.2% of cases) 2
• Hypomagnesemia (100% of cases) 2
• Hypocalcemia (92.5% of cases) 2
• Renal wasting of these electrolytes with normal serum creatinine 2
• Elevated urinary potassium excretion despite hypokalemia

Symptom Profile

• 32.5% of patients are asymptomatic 2
• When symptomatic: paresthesias (27.9%), carpopedal spasms (27.9%) 2
• Severe cases: polyuria, polydipsia, dehydration 3, 6
• Life-threatening: ventricular arrhythmias (torsades de pointes) 5

Critical Management Points

Immediate drug discontinuation is curative - this is the single most important intervention 2, 5, 3, 4

Management Algorithm:

1. Stop the offending drug immediately
2. Aggressive electrolyte repletion (potassium, magnesium, calcium)
3. Fluid resuscitation for volume depletion
4. Monitor for arrhythmias with continuous telemetry if severe hypokalemia present
5. Expect complete resolution within 2 weeks of drug cessation 2

Common Pitfalls

• Continuing the drug while attempting electrolyte correction alone - this will fail as the tubular dysfunction persists 5
• Assuming polymyxin B is safe - it causes the same tubular toxicity as colistin despite marketing claims 3, 4
• Missing the diagnosis in asymptomatic patients - one-third have no symptoms despite severe electrolyte derangements 2
• Re-challenging with the same drug - causes immediate recurrence of the syndrome 4
• Overlooking drug-induced causes in transplant patients on tacrolimus who develop electrolyte disturbances 6

The key distinguishing feature from true Bartter syndrome is normal baseline renal function before drug exposure and complete reversibility upon drug withdrawal 2.